To include your compound in the COVID-19 Resource Center, submit it here.

AbbVie reports Phase III psoriasis data for IL-23 mAb risankizumab

AbbVie Inc. (NYSE:ABBV) said risankizumab (BI 655066) met the co-primary and all ranked secondary endpoints in 3 double-blind, international Phase III trials to treat moderate to severe chronic plaque psoriasis. The company did not respond to inquiries regarding next steps for the humanized IgG1 mAb that binds and neutralizes the p19 subunit of IL-23.

In the identical ultIMMa-1 and

Read the full 582 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE